Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide Bioavailability Study in Healthy Subjects
NCT07071974Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2025
- Primary completion
- Oct 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of survodutide in obesity and Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to the last quantifiable data point at 22 days and Maximum measured concentration in plasma at 22 days. Started Jul 2025; status: completed.
02
Drugs
03
Conditions
obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT07071974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071974.